'Early screening of digestive tract tumors is difficult to rely solely on a certain technology, and it is necessary to play a' combination of fists '. You can use a technology to achieve home 'primary screening', see if you belong to the high-risk group, and then go to the medical institution for fine screening, confirm whether it is early cancer, and then the doctor for further diagnosis and treatment. When you combine different techniques, you get better screening results.' Wang Guiqi, a member of the CPPCC National Committee and director of the endoscopy department of the Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out.
Wang Guiqi (second from right), Yang Aiming (second from left), Zhang Lianglu (first from left)
People's Daily Health Client 2022 'Two Sessions Health Policy'
On March 12, Wang Guiqi, a member of the CPPCC National Committee and director of Endoscopy Department of Cancer Hospital of Chinese Academy of Medical Sciences, Yang Aiming, a member of the CPPCC National Committee and director of gastroenterology Department of Peking Union Medical College Hospital, and Zhang Lianglu, chairman and CEO of Wuhan Emison Life Technology Co., Ltd. visited the digestive tract cancer special session of People's Daily Health Client 2022. To discuss the prevention and control of gastrointestinal cancer.
'The Healthy China 2030 goal states that it is necessary to improve the early diagnosis rate and 5-year survival rate of cancer in key areas. In terms of digestive tract tumors, both the number of cases and the number of deaths in China account for about 1/3 of the world, and digestive tract tumors are especially high in rural areas.' In view of this situation, Wang Guiqi pointed out that he hopes to further do a good job in the prevention and treatment of cancer in rural areas.
Wang Guiqi introduced that among the important factors leading to the return of rural people to poverty, 40% is health, 20% is accidental disability, it can be said that 60% are related to medical health and health, and a series of health and health policies should be adopted to protect the health of grassroots people. Therefore, he proposed at this year's national two sessions that on the basis of the coverage of the current rural cancer screening early diagnosis program, by 2030, the tumor screening will further cover 750 million rural people in 2,860 counties across the country.
Yang Aiming, a member of the National Committee of the Chinese People's Political Consultative Conference and director of the Department of Gastroenterology of Peking Union Medical College Hospital, has been committed to the promotion of cancer early screening, and he believes that to improve the early diagnosis and treatment of cancer, doctors first need to pay attention to it. If doctors pay attention to tumor screening, the early diagnosis rate of patients will be significantly improved. The second is the need for common people's approval. In the past, people felt that doing a gastroenteroscope was very painful and unnecessary, and through the promotion of popular science work, many people paid attention to this piece, and many people took the initiative to come to the hospital and ask, 'Should I do a gastroenteroscope at my age?'
Although gastroenteroscopy is a great tool to achieve early screening of digestive tract tumors, it is not realistic to let everyone do this examination, and it also needs the blessing of some new technologies.
'Before endoscopy, it is necessary to find an effective preliminary screening technology with good patient compliance, so that people can identify whether they are high-risk groups of esophageal cancer or stomach cancer at the grassroots or community, and if they are high-risk groups, they can do fine examination and further diagnosis and treatment of gastrointestinal endoscopy, which can improve the efficiency of screening.' Wang Guiqi pointed out.
Yang Aiming said that in the near future, it may be possible to find out which patients are high-risk groups through blood tests or stool tests, so that the scope of screening can be further narrowed, so that these patients can do gastroenteroscopy, we can really achieve wide coverage and early screening.
Zhang Lianglu, chairman and CEO of Wuhan Emison Life Technology Co., LTD., pointed out that in the face of the growing demand for early cancer screening and early diagnosis, and the contradiction between the relative shortage of medical resources, the industry needs to provide more convenient, more non-invasive and more accurate detection methods.
In recent years, there has been a lot of progress in early screening and early diagnosis of tumors by molecular detection, such as the rapid development of DNA methylation, gene mutation, metabolomics and multi-omics techniques in tumor markers. There is increasing evidence that DNA methylation is currently the most suitable type of tumor marker for early screening of cancer, especially for digestive system tumors. The State Drug Administration has also approved a number of tumor early screening and early diagnosis products based on gene methylation, of which bowel cancer is relatively large, and these products have gradually entered the clinic.
Over the past few years, Amison has developed products around early screening and early detection of cancer. Zhang Lianglu introduced that in terms of fecal DNA detection for bowel cancer, a clinical study led by Peking Union Medical College Hospital conducted joint detection for the detection targets of two genes, the detection sensitivity of colon cancer can reach more than 95%, and the detection rate of precancerous lesions can reach more than 63%, hoping that related products can serve the clinic as soon as possible.
Copy the link below to view a replay of the live broadcast
https://m.peopledailyhealth.com/trailerDetial?contentId=1dff7b55652d4bb68ddc495ef001249a
About Emison colorectal cancer tumor detection product Alchangkang
More product details
For enquiries, please call 17378090801
With outstanding product performance, Emison Life Technology has won four rounds of hundreds of millions of yuan of financing and strong support from governments at all levels, and has won various honorary titles.
Behind the excellent clinical performance and technical platform is the unswerving heart of doctors, and escorting the life and health of the public is the persistent pursuit of Emison Life Technology!
Cancer early screening, beat cancer
Emison Life Technology, keep moving!
Wonderful past
[Evaluation by many experts from the Ministry of Industry and Information Technology: reaching the international advanced level] The development and application of Emison's double-target high-efficiency non-invasive fecal DNA methylation detection kit for colorectal cancer passed the evaluation of scientific and technological achievements of the Ministry of Industry and Information Technology
Authoritative release! | Alchangkang ® double target fecal DNA detection technology has been recognized by international authoritative journals
Get the authoritative certification again! | Alchangkang@multi-center clinical research results were published again in authoritative international journals (impact factor 5.568)
Emison Life Technologies has been appointed as the Vice President of the International EU-China Health Promotion Association | to work together to empower global health and save hundreds of millions of families from the pain of cancer
【 Congratulations 】 Emison Life Technology was selected as the '2021 Optical Valley Startup Star'!
Congratulations to Zhang Lianglu, founder of Emison Life Science and Technology, who was awarded the title of 'Advanced Worker' by Hubei Pharmaceutical and Medical Device Clinical Evaluation Society!
MEDICA this small booth, attracting global attention
2021 World Life Technology Conference was held! Emison tops the TOP10 Tech Startups list
About Emison Life Technologies
Emison Life Technology focuses on the early detection of high-incidence malignant tumors, providing genetic detection services for digestive system tumors (bowel cancer, stomach cancer, liver cancer, esophageal cancer, pancreatic cancer), gynecological tumors (cervical cancer, endometrial cancer), urinary system tumors (bladder cancer), pancancer and other high-incidence malignant tumors.
The company has been based on local development for many years, the core technology is independent and controllable, and the core members come from well-known universities in the United States, Japan, Italy and other places and domestic double first-class universities. After several years of accumulation, a set of diversified product detection system with methylation navigation technology as the core was established. After tens of thousands of clinical sample verification, screening sensitivity and specificity have reached the industry-leading level! The company has applied for 55 patents, published more than 10 cutting-edge research results, and has become one of the few multi-cancer screening service providers in the world and an early-stage tumor detection enterprise authorized by foreign technology License-out.
